Skip to content

Author

M. Zheng

We have 7 of 185 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

A multicenter multistate modeling on the natural history of liver decompensation: Longitudinal analysis of 1777 patients

Background: Cirrhosis often remains silent until decompensation, after which survival deteriorates sharply. Contemporary, transition-aware estimates are limited, especially in Asian-predominant cohorts. We analyzed trajectories from compensated advanced chronic liver disease (cACLD) through sequential decompensations t...

E. Tan, N. S. Tang, N. Syn et al. · 0 citations
Open access Oct 2026

Hepatic Lipid Stress Drives Metabolic Dysfunction‐Associated Steatohepatitis Progression through FTO O‐GlcNAcylation‐Induced m6A Demethylation of HRAS

ABSTRACT Metabolic dysfunction‐associated steatohepatitis (MASH) is driven by nutrient stress through incompletely defined epigenetic mechanisms. This study demonstrates that lipid stress activates the hexosamine biosynthesis pathway (HBP), elevating O‐linked β‐N‐acetylglucosamine (O‐GlcNAc) modification of the N6‐meth...

Jia-Xin Yin, Yan-Lai Zhang, Qun Liu et al. · 0 citations
Sep 2026

PDCD4-driven steatosis via the HNF4A/GK axis is attenuated by the natural compound isosinensetin.

BACKGROUND Programmed cell death factor 4 (PDCD4) has been implicated in various metabolic disorders. However, its role and underlying mechanisms in metabolic dysfunction-associated steatotic liver disease (MASLD) have not been fully elucidated. PURPOSE This study aimed to define the role of PDCD4 in hepatic steatosi...

Xiao-Na Cheng, Kai-Kai Lu, Lu-Yun Yang et al. · 0 citations
Sep 2026

Cardiovascular-kidney-metabolic syndrome and the risk of liver-related and cardiovascular events across the steatotic liver disease spectrum.

A higher CKM stage is associated with an increased long-term risk of MACEs and LREs across the SLD spectrum, and obesity and hypertension are the primary contributors to both outcomes, and diabetes additionally contributes to LREs.

Qiong-Yue Fan, Li-You Lian, Tian-Yi Xia et al. · 0 citations
Aug 2026

Activation of the KPNA2-mediated nuclear import of PPARα by KIF13B mitigates alcohol-associated liver steatosis.

This study identifies KIF13B as a novel regulator of hepatic lipid homeostasis in ALD via the KIF13B-KPNA2-PPARα axis, enhancing KPNA2 mediated nuclear import, particularly in combination with PPARα activation, represents a promising therapeutic strategy for ALD.

Kai-Kai Lu, Si Mei, Lian-Xing Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.